Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE consults on breast cancer drug prevention

  • Comment

Women with a strong family history of breast cancer could be offered drugs by the NHS as a prevention strategy.

The National Institute for Health and Clinical Excellence is currently in the process of updating its clinical guideline on familial breast cancer.

It began a consultation today on a draft version of the guideline with new, provisional recommendations relating to genetic testing, screening and the use of preventive treatments.

This includes for the first time the use of tamoxifen or raloxifene as treatments to prevent breast cancer.

Chris Askew, chief executive of Breakthrough Breast Cancer, described the draft guidance as an “historic step for the prevention of breast cancer”.

“It is the first time drugs have ever been recommended for reducing breast cancer risk in the UK,” he said. 

“This is exciting as, even though most women do not have a significant family history of the disease, it’s crucial that those who do have an array of options to help them control their risk.”

Stakeholders have until Monday 25 February 2013 to submit comments to the NICE consultation.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs